IN2014DN11027A - - Google Patents

Info

Publication number
IN2014DN11027A
IN2014DN11027A IN11027DEN2014A IN2014DN11027A IN 2014DN11027 A IN2014DN11027 A IN 2014DN11027A IN 11027DEN2014 A IN11027DEN2014 A IN 11027DEN2014A IN 2014DN11027 A IN2014DN11027 A IN 2014DN11027A
Authority
IN
India
Prior art keywords
compound
treatment
subunit
disorders
responsive
Prior art date
Application number
Other languages
English (en)
Inventor
Janus Schreiber Larsen
Magnus Gustafsson
Carsten Jessen
Original Assignee
Aniona Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aniona Aps filed Critical Aniona Aps
Publication of IN2014DN11027A publication Critical patent/IN2014DN11027A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41921,2,3-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IN11027DEN2014 2012-06-26 2013-06-25 IN2014DN11027A (hu)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261664288P 2012-06-26 2012-06-26
DKPA201270369 2012-06-26
PCT/EP2013/063194 WO2014001282A1 (en) 2012-06-26 2013-06-25 A phenyl triazole derivative and its use for modulating the gabaa receptor complex

Publications (1)

Publication Number Publication Date
IN2014DN11027A true IN2014DN11027A (hu) 2015-09-25

Family

ID=49782300

Family Applications (1)

Application Number Title Priority Date Filing Date
IN11027DEN2014 IN2014DN11027A (hu) 2012-06-26 2013-06-25

Country Status (13)

Country Link
US (2) US9475797B2 (hu)
EP (1) EP2885290B1 (hu)
JP (1) JP6223443B2 (hu)
KR (1) KR20150033679A (hu)
CN (1) CN104411703A (hu)
AU (1) AU2013283488A1 (hu)
BR (1) BR112014032501A2 (hu)
CA (1) CA2876780A1 (hu)
IL (1) IL235991A (hu)
IN (1) IN2014DN11027A (hu)
MX (1) MX2014014872A (hu)
RU (1) RU2014149123A (hu)
WO (1) WO2014001282A1 (hu)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR102019014802A2 (pt) * 2018-07-20 2020-02-04 Boehringer Ingelheim Int difluorometil-fenil triazóis
TW202202495A (zh) 2020-03-26 2022-01-16 匈牙利商羅特格登公司 作為gamma-胺基丁酸A受體次單元alpha 5受體調節劑之㖠啶及吡啶并〔3,4-c〕嗒𠯤衍生物
JP2023525130A (ja) * 2020-05-13 2023-06-14 エフ. ホフマン-ラ ロシュ アーゲー Gaba a alpha5 pamとしての新規トリアゾリル誘導体
HUP2100338A1 (hu) 2021-09-29 2023-04-28 Richter Gedeon Nyrt GABAA ALFA5 receptor modulátor hatású biciklusos aminszármazékok
CN116462664A (zh) * 2022-03-08 2023-07-21 上海赛默罗生物科技有限公司 吡唑环类化合物、其制备方法、组合物及应用

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2196181T3 (es) 1995-11-01 2003-12-16 Novartis Ag Derivados de purina y proceso para su preparacion.
FR2741881B1 (fr) 1995-12-01 1999-07-30 Centre Nat Rech Scient Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
CA2314401A1 (en) 1997-12-22 1999-07-01 Du Pont Pharmaceuticals Company Nitrogen containing heteroaromatics with ortho-substituted p1's as factor xa inhibitors
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
US7115589B2 (en) 1999-12-17 2006-10-03 Ariad Pharmaceuticals, Inc. Purine derivatives
AU2441701A (en) 1999-12-17 2001-06-25 Ariad Pharmaceuticals, Inc. Purine derivatives
WO2001044260A2 (en) 1999-12-17 2001-06-21 Ariad Pharmaceuticals, Inc. Novel purines
GB2378180B8 (en) 2001-06-27 2009-10-21 Cyclacel Ltd New purine derivatives
US7262176B2 (en) 2001-08-08 2007-08-28 Cv Therapeutics, Inc. Adenosine A3 receptor agonists
US20030078232A1 (en) 2001-08-08 2003-04-24 Elfatih Elzein Adenosine receptor A3 agonists
EP1578722A4 (en) 2001-10-12 2006-09-06 Irm Llc KINASEINHIBITOR SCAFFOLD AND METHOD FOR THE PRODUCTION THEREOF
US20060009642A1 (en) 2001-10-12 2006-01-12 Irm Llc, A Delaware Limited Liability Company Methods for the synthesis of substituted purines
US20030229105A1 (en) 2002-05-21 2003-12-11 Cyclacel Limited Treatment of autoimmune disorders
US20030139427A1 (en) 2002-08-23 2003-07-24 Osi Pharmaceuticals Inc. Bicyclic pyrimidinyl derivatives and methods of use thereof
US20050288503A1 (en) 2002-09-06 2005-12-29 Adams Jerry L Novel compounds
JP2007502776A (ja) 2003-08-15 2007-02-15 アイアールエム・リミテッド・ライアビリティ・カンパニー Rtk阻害剤としての6−置換アニリノプリン類
US20050165029A1 (en) 2004-01-13 2005-07-28 Ambit Biosciences Corporation Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases
WO2005080377A1 (ja) 2004-02-20 2005-09-01 Kirin Beer Kabushiki Kaisha TGFβ阻害活性を有する化合物およびそれを含んでなる医薬組成物
GB0407723D0 (en) 2004-04-05 2004-05-12 Novartis Ag Organic compounds
FR2876583B1 (fr) 2004-10-15 2007-04-13 Centre Nat Rech Scient Cnrse Utilisation de derives de purines pour la fabrication de medicaments pour le traitement de la mucoviscidose et de maladies liees a un defaut d'adressage des proteines dans les cellules
GB0500785D0 (en) 2005-01-14 2005-02-23 Novartis Ag Organic compounds
GB0505219D0 (en) 2005-03-14 2005-04-20 Novartis Ag Organic compounds
US8252806B2 (en) 2005-03-14 2012-08-28 Neurosearch A/S Potassium channel modulating agents and their medical use
US20090036475A1 (en) 2005-03-22 2009-02-05 Neurosearch A/S Pyrazolyl-Pyrimidines as Potassium Channel Modulating Agents and Their Medical Use
WO2006125211A1 (en) 2005-05-19 2006-11-23 Cv Therapeutics, Inc. A1 adenosine receptor agonists
JP2009508905A (ja) 2005-09-19 2009-03-05 エフ.ホフマン−ラ ロシュ アーゲー GABAAα5逆アゴニストとしてのイソオキサゾロ誘導体
CA2625301A1 (en) 2005-10-11 2007-04-19 F. Hoffmann-La Roche Ag Isoxazole derivatives
JP2009514924A (ja) 2005-11-09 2009-04-09 エフ.ホフマン−ラ ロシュ アーゲー 3−アリール−イソオキサゾール−4−カルボニル−ベンゾフラン誘導体
JP2009519995A (ja) 2005-12-20 2009-05-21 ノイロサーチ アクティーゼルスカブ 呼吸器疾患の治療のためのカリウムチャンネル調節剤としての2−ピリジン−2−イル−キナゾリン誘導体
CA2633425A1 (en) 2005-12-23 2007-06-28 F. Hoffmann-La Roche Ag Aryl-isoxazolo-4-yl-oxadiazole derivatives
AU2006331363B2 (en) 2005-12-27 2012-07-05 F. Hoffmann-La Roche Ag Aryl-isoxazol-4-yl-imidazo[1, 5-a]pyridine derivatives
BRPI0620773A2 (pt) 2005-12-27 2011-11-22 Hoffmann La Roche derivados de aril-isoxazol-4-il-imidazol
EA014720B1 (ru) * 2006-05-24 2011-02-28 Эли Лилли Энд Компани Соединения и способы модуляции fxr
AU2007267183B2 (en) 2006-05-31 2011-10-20 F. Hoffmann-La Roche Ag Aryl-4-ethynyl-isoxazole derivatives
EP1894924A1 (en) 2006-08-29 2008-03-05 Phenex Pharmaceuticals AG Heterocyclic FXR binding compounds
EP1894928A1 (en) 2006-08-29 2008-03-05 PheneX Pharmaceuticals AG Heterocyclic fxr binding compounds
JP2010502674A (ja) 2006-09-07 2010-01-28 ノイロサーチ アクティーゼルスカブ カリウムチャンネル調節剤として有用なピリジニル−ピリミジン誘導体
WO2008040753A1 (en) 2006-10-03 2008-04-10 Neurosearch A/S Indazolyl derivatives useful as potassium channel modulating agents
CN101622001A (zh) 2007-01-26 2010-01-06 Irm责任有限公司 作为激酶抑制剂用于治疗疟原虫相关疾病的嘌呤化合物和组合物
WO2008092942A2 (en) 2007-02-02 2008-08-07 Neurosearch A/S Pyridinyl-pyrazole derivatives and their use as potassium channel modulators
NZ579248A (en) 2007-03-28 2011-08-26 Neurosearch As Purinyl derivatives and their use as potassium channel modulators
WO2008116911A1 (en) 2007-03-28 2008-10-02 Neurosearch A/S Purinyl derivatives and their use as potassium channel modulators
CN101965344B (zh) 2007-06-22 2013-03-06 弗·哈夫曼-拉罗切有限公司 异*唑-咪唑衍生物
WO2009050199A1 (en) 2007-10-17 2009-04-23 Novartis Ag Purine derivatives as adenosine al receptor ligands
KR101175859B1 (ko) 2007-12-04 2012-08-24 에프. 호프만-라 로슈 아게 이속사졸로-피라진 유도체
SI2227467T1 (sl) 2007-12-04 2015-03-31 F. Hoffmann-La Roche Ag Derivati izoksazolo-piridina
US7943619B2 (en) * 2007-12-04 2011-05-17 Hoffmann-La Roche Inc. Isoxazolo-pyridazine derivatives
EP2128158A1 (en) 2008-05-26 2009-12-02 Phenex Pharmaceuticals AG Heterocyclic cyclopropyl-substituted FXR binding compounds
GEP20135957B (en) * 2008-06-19 2013-11-11 Takeda Pharmaceuticals Co Heterocyclic compound and usage thereof
WO2010034707A1 (en) 2008-09-26 2010-04-01 Neurosearch A/S Substituted purinyl-pyrazol derivatives and their use as potassium channel modulators
US20110237607A1 (en) 2008-09-26 2011-09-29 Neurosearch A/S Substituted purinyl-pyrazol derivatives and their use as potassium channel modulators
PE20100362A1 (es) 2008-10-30 2010-05-27 Irm Llc Derivados de purina que expanden las celulas madre hematopoyeticas
US8389550B2 (en) 2009-02-25 2013-03-05 Hoffmann-La Roche Inc. Isoxazoles / O-pyridines with ethyl and ethenyl linker
US8222246B2 (en) 2009-04-02 2012-07-17 Hoffmann-La Roche Inc. Substituted isoxazoles
US8227461B2 (en) 2009-04-30 2012-07-24 Hoffmann-La Roche Inc. Isoxazoles
WO2010127968A1 (en) 2009-05-05 2010-11-11 F. Hoffmann-La Roche Ag Isoxazole-pyridazine derivatives
CN102414205B (zh) 2009-05-05 2014-11-05 弗·哈夫曼-拉罗切有限公司 异噁唑-吡唑衍生物
KR101354335B1 (ko) 2009-05-05 2014-02-19 에프. 호프만-라 로슈 아게 인지 장애의 치료에 사용되는 gaba a 수용체 역 작용제로서의 아이속사졸-티아졸 유도체
MX2011011489A (es) 2009-05-05 2011-11-18 Hoffmann La Roche Derivados de isoxazol-piridina.
EP2427457B1 (en) 2009-05-07 2013-07-17 F.Hoffmann-La Roche Ag Isoxazole-pyridine derivatives as gaba modulators
EP2289883A1 (en) 2009-08-19 2011-03-02 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
US8742097B2 (en) * 2010-11-09 2014-06-03 Hoffmann-La Roche Inc. Triazole compounds I
ES2536667T3 (es) * 2010-11-09 2015-05-27 F. Hoffmann-La Roche Ag Derivados de triazol como ligandos de receptores Gaba
US8466181B2 (en) 2010-12-10 2013-06-18 Hoffmann-La Roche Inc. 1,2,3-triazole-imidazole compounds

Also Published As

Publication number Publication date
CA2876780A1 (en) 2014-01-03
JP6223443B2 (ja) 2017-11-01
WO2014001282A1 (en) 2014-01-03
EP2885290A1 (en) 2015-06-24
JP2015521643A (ja) 2015-07-30
MX2014014872A (es) 2015-08-06
AU2013283488A1 (en) 2015-01-15
IL235991A (en) 2017-07-31
US20160115155A1 (en) 2016-04-28
US9884848B2 (en) 2018-02-06
EP2885290B1 (en) 2017-10-18
KR20150033679A (ko) 2015-04-01
RU2014149123A (ru) 2016-08-20
CN104411703A (zh) 2015-03-11
BR112014032501A2 (pt) 2017-06-27
US9475797B2 (en) 2016-10-25
US20170114045A1 (en) 2017-04-27
IL235991A0 (en) 2015-02-01

Similar Documents

Publication Publication Date Title
PH12014501900A1 (en) Oxazolidin-2-one compounds and uses thereof as pi3ks inhibitors
MD20150091A2 (ro) Compuşi antivirali
PH12016500094A1 (en) Autotaxin inhibitors
MX357504B (es) Derivado de feniltriazol y su uso para modular complejo del receptor gabaa.
IN2015DN00847A (hu)
PH12014501514A1 (en) New azetidine derivatives, pharmaceutical compositions and uses thereof
IN2014MN02459A (hu)
TN2014000016A1 (en) 4 - piperidinyl compounds for use as tankyrase inhibitors
MD4583B1 (ro) Piridinone biciclice noi
IN2015DN00372A (hu)
JO3334B1 (ar) مشتقات أوكسازوليدين-2- أون – بيريميدين
MX2014000964A (es) Derivados aza heterociclicos sustituidos.
IN2014CN03854A (hu)
PH12017500595A1 (en) Aldosterone synthase inhibitors
IN2014DN11027A (hu)
PH12017500089A1 (en) Aldosterone synthase inhibitors
IN2013DN02555A (hu)
MX2014000963A (es) Derivados de carboxamida y urea aromaticos biciclicos sustituidos como ligandos del receptor de vanilloide.
MX2015005312A (es) Derivados de 1h-indazol-3-carboxamida y uso de los mismos como antagonistas de p2y12.
WO2012174552A3 (en) Cathepsin inhibitors for treating microglia-mediated neuron loss in the central nervous system
IN2014KN00849A (hu)
AU2019268209A1 (en) Compounds for the treatment of seizures and other central nervous system disorders and conditions
TN2014000340A1 (en) Oxazolidin- 2 -one compounds and uses thereof as pi3ks inhibitors
LV14738A (lv) Kardiovaskulāras iedarbības preparāts
TN2013000122A1 (en) Oxadiazole inhibitors of leukotriene production